BAIYUNSHAN PH

Shares rose 0.6% to close at HK$15.95, with morning trading wavering (dipping to HK$15.82 before a recovery) while afternoon momentum strengthened, pushing toward the day's high of HK$15.95 in the final 30 minutes. This upside is supported by several factors: a fresh strategic partnership announcement with Sanyou Bio to advance innovative radiopharmaceuticals and radiodiagnostics, bolstering the company's pipeline; Q1 2026 results rebounding with revenue of HK$26.39 billion (+9.65% year-on-year) and net profit of HK$2.02 billion (+3.68% year-on-year), reversing Q4's loss-making position; and a lean valuation at PE 7.77 and PB 0.58. That said, the stock remains 21.81% below its 52-week peak of HK$20.4, though it has recovered 13.93% from the June low of HK$14, suggesting modest rebound momentum.

Baiyunshan closed nearly flat today as the morning session's peak of HK$16.05 gave way to afternoon weakness, reflecting market indecision between recent positive catalysts and valuation appeal. On July 30, the company announced a strategic collaboration with Sanyou Bio to advance radiopharmaceuticals and radiodiagnostic products—a meaningful near-term catalyst. Q1 financial results underscored ongoing growth with revenue reaching HK$26.391 billion (up 9.65% year-over-year) and net profit of HK$2.022 billion (up 3.68% year-over-year). The stock has recovered from its 52-week low of HK$14 set on June 28, yet remains down over 21% from the 52-week high of HK$20.40 and down 12.18% year-to-date. While valuation remains compressed—with a P/E of 7.77 and P/B of 0.58—and a 6% dividend yield offers attractive income, underlying market skepticism toward growth sustainability and other fundamentals continue to suppress further appreciation.

Stock displayed V-shaped price action today, declining to near 52-week low of 15.64 HKD in morning session before staging afternoon rebound to close at 15.83 HKD, essentially flat versus prior close of 15.82 HKD. With year-to-date losses of 12.78% and current price 22.4% below 52-week high of 20.4 HKD, the decline has attracted value-oriented buying. Fundamentals support recovery: Q1 2026 revenue reached 26.39 billion HKD, up 9.65% year-on-year, while net profit of 2.02 billion HKD rose 3.68% YoY, reversing Q4's loss-making quarter and delivering EPS of 1.24 HKD. Current valuation metrics are extremely attractive with PE of 7.71 and PB of 0.57, paired with dividend yield of 6.04%. Recent strategic partnership with Sanyou Bio to develop innovative radiopharmaceuticals and radiodiagnostics signals pipeline progress. However, stock remains well below 52-week highs, requiring sustained fundamental momentum to break higher.

Baiyunshan closed up 1.73% to HK$15.820 today, touching a morning low of HK$15.550 at 09:32 before rebounding to a daily high of HK$15.860 at 10:08, with afternoon trading confined to a HK$15.770-15.850 range. The gain was primarily driven by the announcement of a strategic collaboration with Sanyou Bio on innovative radiopharmaceuticals and radiodiagnostics. Fundamentally, Q1 revenue reached HK$263.9 billion with 9.65% year-on-year growth, while net profit of HK$2.023 billion grew 3.68% year-on-year, with ROE at 18.45%, reflecting steady business expansion; while Q4 posted a loss, turnaround signs are evident. Valuation-wise, the stock trades at a lean PE of 7.71x, PB of 0.57x, and offers a dividend yield of 6.04%, representing historically attractive levels. The stock has retreated 22.45% from its 52-week high of HK$20.4 set in November 2025, and is down 12.84% year-to-date. However, the daily turnover rate of merely 0.22% indicates limited market participation.

Guangzhou Baiyunshan Pharma declined 2.2% to 15.55 HKD today, with morning weakness extending to accelerated selling in the afternoon session. While Q1 financial results demonstrated revenue growth of 9.65% and net profit increase of 3.68% year-on-year, broader market sentiment toward the pharmaceutical sector remains cautious, with profit-taking pressures persisting since the rebound from the 52-week low of 14 HKD established in late June. Year-to-date the stock has fallen 14.33%, currently trading roughly 24% below the 52-week high of 20.40 HKD reached in November. Valuations remain deeply depressed with P/E at 7.58x, P/B at 0.56x, and a notably attractive dividend yield of 6.15%. Recent strategic collaboration with Sanyou Bio on radiopharmaceuticals and radiodiagnostics, combined with ongoing expansion in Central Asia, underscores continued investment in pipeline innovation.